Bioxel Pharma Inc.
TSX VENTURE : BIP

Bioxel Pharma Inc.

August 12, 2008 10:28 ET

Bioxel Grants Options to its New President and Chief Executive Officer

SAINTE-FOY, QUEBEC--(Marketwire - Aug. 12, 2008) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announces that upon the signing of the employment contract of Olivier Meyer as President and Chief Executive Officer effective July 16, 2008, the Corporation's Board of Directors granted him 150,000 stock options at a price of $0.11 per option and expiring July 15, 2013.

ABOUT BIOXEL PHARMA

Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane active pharmaceutical ingredients and proprietary products for improved cancer therapy. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis and cardiovascular disease.

The TSX Venture Exchange accepts no responsibility for the adequacy or accuracy of this press release.

Contact Information